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Abstract
A hallmark of HIV-1 infection is the continuously declining number of the virus’ predominant
target cells, activated CD4+ T cells. With diminishing CD4+ T cell levels, the capacity to uti-
lize alternate cell types and receptors, including cells that express low CD4 receptor levels
such as macrophages, thus becomes crucial. To explore evolutionary paths that allow HIV-
1 to acquire a wider host cell range by infecting cells with lower CD4 levels, we dissected the
evolution of the envelope-CD4 interaction under in vitro culture conditions that mimicked the
decline of CD4high target cells, using a prototypic subtype B, R5-tropic strain. Adaptation to
CD4low targets proved to severely alter envelope functions including trimer opening as indi-
cated by a higher affinity to CD4 and loss in shielding against neutralizing antibodies. We
observed a strikingly decreased infectivity on CD4high target cells, but sustained infectivity
on CD4low targets, including macrophages. Intriguingly, the adaptation to CD4low targets
altered the kinetic of the entry process, leading to rapid CD4 engagement and an extended
transition time between CD4 and CCR5 binding during entry. This phenotype was also
observed for certain central nervous system (CNS) derived macrophage-tropic viruses,
highlighting that the functional perturbation we defined upon in vitro adaptation to CD4low tar-
gets occurs in vivo. Collectively, our findings suggest that CD4low adapted envelopes may
exhibit severe deficiencies in entry fitness and shielding early in their evolution. Considering
this, adaptation to CD4low targets may preferentially occur in a sheltered and immune-privi-
leged environment such as the CNS to allow fitness restoring compensatory mutations to
occur.
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Author summary
Untreated HIV-1 infection leads to a gradual depletion of CD4+ T cells forcing the virus
to continuously adapt to an ever-decreasing number of suitable target cells. Our data
based on experiments in a highly controlled in vitro setting describe one avenue of enve-
lope adaptation that allows the virus to infect target cells expressing low amounts of CD4
such as macrophages. Analysis of the functional envelope phenotypes associated with
adaptation of the virus to infect target cells expressing low levels of CD4 highlighted
altered entry kinetics of the virus. These alterations resulted in extended exposure of
CD4-induced neutralization sensitive epitopes in combination with an increased sensitiv-
ity to neutralizing antibodies targeting the CD4 binding site and the V3 loop. Interest-
ingly, a similar phenotype was observed for macrophage-tropic HIV-1 isolates derived
from the central nervous system (CNS) of infected individuals raising the possibility that
the immune-privileged CNS may favor the development of macrophage-tropic / low CD4
level utilizing envelope variants.
Introduction
The infection cycle of HIV-1 is intimately linked with the CD4 receptor on target cells. Entry
is initiated by the binding of the viral envelope glycoprotein gp120 to CD4, necessitating a
high conservation of the CD4 binding site (CD4bs) on the viral envelope [1]. At the same time,
the virus faces a humoral immune response targeting the CD4bs [1–4] and disease progression
decreases the pool of available CD4 expressing target cells [5–8]. During disease progression
multiple forces are therefore acting on the envelope glycoprotein and its interplay with CD4.
How these factors shape envelope functional adaptation, and which combination of selective
forces is responsible for giving rise to viral phenotypes observed at late disease stages remains
unclear. A particular conundrum is the capacity of HIV-1 to maintain high level virus produc-
tion at late disease stages, even when the classical target cells, CD4+ T cells, are heavily depleted
[9–12]. Because of this, it was suggested for some time that HIV-1 resolves to replicate in other
cell types at later stages [13, 14], which can be linked with use of alternative coreceptors
(reviewed in [15–17]). Differential receptor usage most commonly includes varying the capac-
ity of Env to bind CD4 or CCR5, and switching coreceptor use to CXCR4. All of these pheno-
types have been observed in late disease states in vivo [18–22].
HIV-1 enters host cells by first binding to CD4 [23, 24] via the gp120 surface glycoprotein
subunit [25]. CD4 binding triggers conformational changes in gp120 that expose the co-recep-
tor binding sites to attach to either of the two main co-receptors; CCR5 (R5) [26, 27] or
CXCR4 (X4) [28]. The dynamics of CD4 and CCR5 and/or CXCR4 use are important determi-
nants of cellular tropism and transmission of HIV-1. Receptors are expressed independently
in various combinations and at different levels on a multitude of human cells, rendering spe-
cific cell types differentially susceptible to specific envelope variants [22, 29, 30]. R5 tropic
envelopes almost exclusively establish infection [31–34] and allow for the infection of activated
effector memory CD4+ T cells [35], macrophages, and dendritic cells [36]. A switch in co-
receptor use, from R5 to X4 tropism, is well documented at later disease stages, has been
observed in 20–50% of patients [37–41] and described in non-human primates (NHP) [42,
43]. CXCR4 usage results in an expansion of cellular tropism of the virus to include naïve
CD45RA+ CD4+ T-cells, which lack CCR5 expression [36], and has often been associated with
disease progression [32, 44–47]. Likewise, increased replicative fitness of R5 viruses in later
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stages of infection has also been linked with rapid disease progression [44, 48–54] though this
is not universal [55].
During the course of infection, the HIV-1 envelope must adapt to facilitate replication
despite a decrease in its preferred CD4+ target cell population. Acute infection rapidly depletes
the activated CD4+ T cells expressing high CCR5 co-receptor levels abundant in the GALT
(gut-associated-lymphoid-tissue) and the genital mucosa [10, 56]. In addition to the death of
infected cells, the dramatic reduction in total CD4+ T cell counts observed in HIV-1 infection
is considered mainly due to apoptotic and bystander cell death [57–60] and possibly killing of
CD4+ T cells following abortive infection with HIV via pyroptosis [7, 12].
In the progression of untreated infection, the virus thus needs to expand its cellular tropism
by gaining access to different tissue compartments and adapting to utilize suboptimal receptor
levels and different receptors in humans [61, 62] and NHP models [42, 43]. This is well docu-
mented by studies on viruses derived from the central nervous system (CNS). Envelopes from
virus circulating in this compartment often display elevated macrophage tropism that has
mainly been attributed to an improved affinity for CD4. Paired with almost unanimous
R5-usage, increased CD4 affinity allows the virus to infect macrophages expressing low levels
of CD4 [20, 21, 63–68]. Macrophage tropism has also been attributed to an increased affinity
for CCR5 [20, 69–71]. Consequently, at late disease stages the ability to use low levels of CD4
and R5 or X4, or dual (R5X4) tropism, can provide these envelopes with a broad cellular tro-
pism including macrophages, T cells, DCs and even microglia [21, 36, 63, 66, 69, 72–74].
Thus, the co-evolutionary arms race between the immune system and virus, in combination
with the ever-decreasing availability of target cells, produces a complex composition of possi-
ble envelope-receptor tropisms specific to disease stages and/or body compartments. Numer-
ous studies have phenotypically characterized envelopes displaying altered receptor- and
cellular- tropisms. The impressive body of previous work has almost exclusively focused on
identifying associated phenotypes of, and specific mutations associated with, macrophage-tro-
pism derived during infection in vivo. The envelopes used in the literature have been isolated
from patient material and as such have developed in vivo under an undefined collection of
selective forces. One of the foremost phenotypes consistently associated with macrophage tro-
pism is the ability to use low levels of CD4. Our study explores the impact that a CD4low selec-
tive force has on the resulting envelope phenotype when applied in isolation to address the
question whether low CD4 availability by itself is sufficient to generate macrophage tropism.
In this study, we specifically explored the impact of a target cell environment low in available
CD4 receptor numbers (CD4low), as this may gain in importance at late disease stages during
HIV-1 infection. Utilizing an R5 virus isolated from a chronically infected individual, we
exposed it to an artificially induced CD4low PBMC environment using a CD4 D1-domain bind-
ing DARPin that blocks gp120 binding to CD4 [75]. We show that adaptation of the HIV-1
envelope glycoprotein to CD4low PBMC is sufficient to produce a phenotype similar to that
observed in the CNS in vivo, displaying high sensitivity to CD4 and neutralizing antibodies as
well as increased macrophage tropism. Adaptation to CD4low PBMC resulted in evolution of
envelope variants with a higher affinity to CD4 but decreased fitness. Envelopes with a CD4low
adapted phenotype suffer reduced particle infectivity, prolonged entry step transitions and
increased neutralization sensitivity. We lastly extend the observation of long entry step transi-
tions to several extensively described CNS-derived macrophage-tropic Envs [64, 76–79]. In
combination these observations highlight that the emergence of CD4low using viruses must
overcome multiple barriers in vivo, likely requiring a range of compensatory mutations to offset
the reduced neutralization resistance and entry capacity, providing an explanation as to why
virus strains with these properties have been observed before the onset of potent neutralization
responses [80] and have often been isolated from the immune-privileged CNS [66, 74, 81].
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Results
Adapting HIV-1 to utilize target cells expressing low amounts of CD4
In the present study we were interested to follow the evolution of the HIV-1 envelope protein
when confronted with the selective pressure of a cell environment with low CD4 receptor
availability. The starting point of our analysis was a subtype B, R5-tropic virus isolate called
NAB01, derived during chronic infection [82, 83]. The process of adaptation of this virus to
low CD4 expressing target cells and the chronology of clones generated to form an envelope
evolution panel for later phenotypic and genotypic characterization is outlined in Fig 1A.
The NAB01 primary isolate was first adapted to replication on PBMC in the absence of neu-
tralizing antibody pressure to allow later dissection of sequence alterations due solely to adap-
tation to CD4low levels [84]. After 39 weeks of adaptation to PBMC culture, the envelope gene
of the NAB01 PBMC-adapted (PA) virus, termed NAB01-PA, was cloned, and inserted into
Fig 1. Directed evolution of HIV-1 to utilize CD4low target cells. Adaptation of HIV-1 to CD4low targets in vitro (A, B). (A) Overview of stepwise
adaptation to CD4low PBMC targets and PBMC reversion cultures with normal CD4 levels and the derived envelope clones. (B) Summary of the 18 week
adaptation to low CD4 expressing target cells. Stepwise decrease in available cell surface CD4 on PBMC was achieved by dose escalation of the CD4
inhibitor DARPin 57.2 (right axis, grey shaded areas). HIV-1 replication as measured by p24 antigen production in culture supernatant on CD4 inhibitor
treated cells (CD4low culture, red) and control culture (untreated PBMC, blue) are shown. (C) Adaptation to CD4low targets increases sensitivity to
CD4-IgG2 (PRO542). Mean neutralization sensitivity (IC50) of envelope-pseudotyped viruses on TZM-bl cells derived from two to seven independent
assays (error bars = SD) are shown. (D) High sensitivity to CD4-IgG2 is paired with high binding capacity of CD4-IgG2 to Env trimer. Simple linear
regression analysis of CD4-IgG2 inhibitory capacity (IC50 values shown in panel C) and binding of CD4-IgG2 to the envelope of the indicated viruses
expressed on 293-T cells. Mean fluorescence intensity = MFI. Data are means of two independent experiments; error bars = SD. (E) Adaptation to CD4low
target cells results in high resistance to CD4 inhibitor compared to wild type HIV-1 isolates. Comparison of IC50 of CD4-blocking DARPin 55.2 against 41
wild-type HIV-1 strains from different clades (black dots, see S3 Table for details on virus panel and individual IC50 values) and the CD4low adaptation
virus panel (colored dots, see legend) probed by Env pseudovirus infection on TZM-bl cells. Data are means of one to three independent experiments.
doi:10.1371/journal.ppat.1006255.g001
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the replication competent TN6 HIV vector backbone [85] to produce the Env-chimeric virus
NAB01-PA-TN6 as a control in a previous study [84]. The NAB01-PA Env clone carried cul-
ture adaptation mutations found previously in independent NAB01 long-term culture viruses
(S2 Fig and [84]). Our in vitro target cell setup with low CD4 availability was designed to
mimic a CD4low target cell environment in an immunological sanctuary site that is not, or
only sub-optimally, reached by neutralizing antibodies, as occurs in the CNS. Employing the
NAB01-PA envelope pre-adapted to growth in PBMC in vitro in absence of an autologous neu-
tralization response allowed us to study the virus envelope evolution in response to alteration
of the CD4 availability in the target cell environment in the following steps.
To mimic a CD4low environment, we cultured NAB01-PA-TN6 on PBMC in the presence
of the CD4 inhibitor DARPin 57.2 which competitively interferes with gp120-CD4 binding
and thus limits the availability of CD4 on PBMC without interfering otherwise with the cells
[75]. Virus was cultured over 18 weeks in the presence of increasing concentrations of DARPin
57.2 or in absence of the inhibitor. The concentration of DARPin 57.2 was incrementally
increased during the cultivation period from 15 nM at the start, to a final concentration of
1500 nM after 18 weeks of culture (Fig 1B). Functional envelope clones capable of free-virus
infection were isolated from both the CD4-DARPin treated and control culture supernatants
(S2 Table). Two unique envelopes, referred to as CD4low.c21 and CD4low.c24, were chosen for
further analysis. CD4low.c24 represented the dominant emerged variant representing the bulk
sequence of the CD4 DARPin treated culture, whereas CD4low.c21 differed from this main
sequence in several positions (S2 Table). Two functional envelopes were isolated from the cor-
responding PBMC control culture and, one PBMCcon.c14, with high similarity to the bulk
sequence and thus representing the main variant, was selected for further characterization (S2
Table).
We next probed if the adaptation to low CD4 levels on target cells results in a stable virus
phenotype or if the envelope reverts to wild type once reintroduced into a high CD4 expressing
environment. The selected envelope clones of the adaptation and control cultures (CD4low.
c21, CD4low.c24, and PBMCcon.c14) were re-cloned into the TN6 vector and cultured indepen-
dently for eight weeks on PBMC in the absence of CD4 inhibitors (termed reversion culture).
Functional envelopes representing the main variants were cloned from each reversion culture,
and referred to as CD4low.c21-rev, CD4low.c24-rev, and PBMCcon.c14-rev (S2 Table) and used
to create Env pseudoviruses and Env chimeric TN6 viruses. In sum we compiled a panel of
eight envelopes derived from the original patient isolate NAB01 which we refer to as the
CD4low adaptation panel, that include the wild type NAB01 Env, the culture adapted control
Envs (NAB01-PA, PBMCcon.c14, PBMCcon.c14-rev), the CD4low adapted Envs (CD4low.c21
and CD4low.c24), and reversion Envs (CD4low.c21-rev and CD4low.c24-rev).
Affinity to CD4 dramatically increases with adaptation to CD4low T cells
To explore if the adaptation to a CD4low environment changed the virus’s interaction with
CD4, we first compared the sensitivity of our CD4low adaptation panel to the tetrameric fusion
protein CD4-IgG2, also known as Pro-542 [86] (Fig 1C). As high sensitivity to CD4-IgG2
denotes a high affinity of the HIV-1 envelope for CD4 [78], changes in sensitivity allowed us to
directly monitor a functional impact of the adaptation to lower CD4 levels. In vitro culture
adaptation to PBMC is known to result in an increased sensitivity to CD4 based inhibitors
[87–89]. In line with this, we observed a 7.9-fold increase in sensitivity to CD4-IgG2 for
NAB01-PA compared to the patient isolated NAB01. The descendant culture adapted clones
PBMCcon.c14 and PBMCcon.c14-rev only slightly increased their sensitivity further (2.9-fold
and 1.6-fold compared to wildtype, respectively), highlighting that NAB01-PA was optimally
Delineating CD4 dependency of HIV-1
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adapted to in vitro PBMC replication (Fig 1C). In contrast, CD4low pressure resulted in a dra-
matic increase in sensitivity to CD4 inhibition for both CD4low.c21 and CD4low.c24 with IC50
values 446.3- and 407- fold lower than wildtype (56.5- and 51.5-fold increased sensitivity rela-
tive to NAB01-PA), respectively, confirming that these viruses have increased their affinity to
CD4 (Fig 1C). However, this high affinity to CD4 was not maintained upon re-exposure to a
high CD4 target cell environment on untreated PBMC. Both viruses partially reverted and lost
8.9- and 11.5- fold sensitivity to CD4-IgG2 compared to the CD4
low clones, for reversion cul-
ture clones CD4low.c21-rev and CD4low.c24-rev, respectively. This suggested a possible fitness
deficit associated with the ability to use low levels of CD4.
To further define the viruses’ affinity for CD4 we compared the binding of CD4-IgG2 to cell
surface-expressed envelope trimers by flow cytometry. The geometric mean fluorescence of
cell-bound CD4-IgG2 inversely correlated with CD4-IgG2 neutralization activity (R
2 = 0.6458,
p = 0.0002; Fig 1D, simple linear regression) confirming that the CD4low adapted strains,
which portray high sensitivity to soluble CD4 neutralization, do indeed have an increased
affinity for CD4. In line with this heightened affinity for CD4, the CD4low viruses were the
least sensitive to CD4-inhibition compared to 41 wild type HIV-1 strains from multiple sub-
types (Fig 1E and S3 Table).
CD4 and CCR5 levels influence differential infection capacity of CD4low
adapted strains
To elucidate the impact of the altered interaction with the CD4 receptor, we next analyzed
how CD4low adapted viruses infect target cells with variable CD4 and CCR5 receptor expres-
sion. To this end we utilized the 293-T cell based HIV-1 receptor affinity profiling system (293
Affinofiles) to express 42 unique combinations of CD4 and CCR5 densities (S1 Fig) as previ-
ously described [90, 91]. This matrix of receptor expression levels covers relevant in vivo CD4
levels and further offers the opportunity to differentiate the influence of CD4 and CCR5 levels
independently of each other. In the un-induced stage, Affinofile cells have been shown to
express CD4 at 0.7 antibody binding sites (ABS) / μm2) and at maximal induction 64 CD4
ABS/μm2 and therefore to reflect the range of CD4 level distribution observed in vivo on
monocytes (3.1 CD4 ABS/μm2), monocyte derived macrophages (3.4 CD4 ABS/μm2) and
CD4+ T cells (78 CD4 ABS/μm2) [21]. We infected induced matrices of Affinofiles and ana-
lyzed the 42 independent conditions by 3-D surface plots (S2 Fig).
To assess the efficacy of infection at different receptor densities, we calculated the relative
infectivity compared to the maximum activity a given Env reached on Affinofiles for each
clone at each Affinofile matrix condition combination (S1 Fig). This analysis highlighted the
differential response to decreasing receptor density exhibited by the CD4low adapted Envs in
comparison with the rest of the panel (Fig 2). Whereas parental and CD4high target exposed
Envs retained only marginal infectivity on targets with low CD4 levels (3% of max for NAB01,
NAB01-PA, and PBMCcon.c14, 5% for PBMCcon.c14-rev), CD4low viruses were markedly
higher (18% and 25% for CD4low.c21 and CD4low.c24, respectively) (Fig 2A).
Employing sensitivity vector analysis for Affinofile data [91], we estimated the relative sen-
sitivity of each envelope to changes in CCR5 and CD4 levels. In this analysis, sensitivity vector
angles 0˚ θ<45˚ indicate a higher sensitivity to changes in CD4 level, while angles between
45˚< θ90˚ reflect higher sensitivity to CCR5, and 45˚ is thereby equal sensitivity to both
receptors. In line with an improved capacity to interact with CD4, the CD4low viruses proved
to be less steered by changes in CD4 than by CCR5 (57.1˚ and 60.4˚ vector for CD4low.c21 and
CD4low.c24, respectively; Fig 2B). Comparing the sensitivity vector angles to the parental and
control viruses (33.3˚-37.0˚) and CD4low-reversion clones (26.8˚ and 36.9˚ for CD4low.c21-rev
Delineating CD4 dependency of HIV-1
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and CD4low.c24-rev, respectively) (Fig 2B), further indicates that the receptor dependency
acquired by adaptation to CD4low targets is unfavorable and not stable, as upon replication in a
normal CD4 T cell environment, the phenotype is rapidly lost. Control envelopes yielded
highly similar values in the vector angle analysis (33.3˚-37.0˚) suggesting that an optimal
dependency for the NAB01 envelope background lies in this range. Of note, the Affinofile sen-
sitivity vector angle was able to elucidate subtle differences in the phenotypes of CD4low.
c21-rev and CD4low.c24-rev. The reversion clones displayed differential avenues of compensa-
tion for the apparently unfit CD4low adaptation once returned to unrestricted activated PBMC
CD4 levels; CD4low.c21-rev showed a markedly lower infectivity compared to CD4low.c24-rev
(S2 Fig) and it reverted to even higher dependency on CD4 and lower sensitivity to CCR5 (vec-
tor angle 26.8˚) than the control viruses (33.3˚-37.0˚; Fig 2B). In contrast, CD4low.c24-rev
recovered infectivity, exhibiting similar levels of infection to the controls on high CD4 cells,
and also developed the highest infectivity of the panel on cells with low CD4. These data sug-
gest that CD4low envelopes have adopted a high tolerance for low levels of CD4, with an associ-
ated increased utilization of CCR5. CNS macrophage-tropic Env infection of Affinofiles
reported similar effects, namely decreased dependence on CD4, altered interaction with CCR5
(compared to paired non-macrophage-tropic envs)[92, 93].
Adaptation to CD4low targets results in marked infectivity loss during free
virus infection but not in cell-cell transmission and cell-fusion
We next measured the capacity of the CD4low virus panel to infect target cells with different
ranges of CD4 and CCR5 levels using single round replicating Env pseudo-viruses (Fig 3A).
We first probed infection on TZM-bl, which were previously estimated to carry 4x105 CD4
and 1.3x104 CCR5 receptors per cell [94], and stimulated PBMC which were estimated to
express a pre-activation average of 6x103 CD4 and 593 CCR5 receptors per cell [29]. In line
with the reported receptor densities, we observed higher absolute infectivity on TZM-bl than
Fig 2. CD4low adapted envelopes infect a wider range of target cells with differential CD4 and/or CCR5
densities. Infection profiles of 293T-Affinofile cells infected with the CD4low panel envelope-pseudotyped
viruses. Affinofiles were induced to express a matrix of 42 unique combinations of CD4 and CCR5 and the
resulting 3D infection profiles were normalized relative to each envelope’s own maximum infection (S1 and S2
Figs). (A) Percent of maximum (high CD4 and high CCR5) level infection retained on cells expressing high
CCR5 (2.5 μM Ponasterone A) and the lowest amounts of CD4 (0 μg/ml Doxycycline). Data are from two
independent induction and infection assays (S1 and S2 Figs). (B) The VERSA sensitivity vector metrics were
calculated by fitting a plane to the 3D surface plots (S2 Fig) as previously described by Johnston et al., 2009,
and the resulting vector angle indicates a preferential response to changes in CD4 (angles towards 0˚) or CCR5
(angles towards 90˚). Vector angles from one of two infection experiments are shown.
doi:10.1371/journal.ppat.1006255.g002
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PBMC (S3 Fig). NAB01, NAB01-PA, and the culture controls PBMCcon.c14, and PBMCcon.
c14-rev, showed infectivity within a 3.6-fold range on both TZM-bl and PBMC (Fig 3). In con-
trast, adaptation to CD4low targets led to a 2.5–24.8 fold and 3.3–13.3 fold loss in infectivity on
TZM-bl and PBMC compared to the parental clone NAB01-PA for CD4low.c21 and CD4low.
c24, respectively. Notably, infectivity was restored in only one of the reversion culture clones:
CD4low.c24-rev (Fig 3A).
We next explored whether the CD4low adaptation may have led to improved spread in cul-
ture via cell-cell transmission to compensate for the attenuated free virus infectivity observed
Fig 3. Adaptation to CD4low targets reduces free virus infectivity despite high fusogenicity. (A) Cell-free virus infectivity is reduced upon adaptation
to CD4low targets. Infectivity of Env-pseudotyped cell-free virus stocks was assessed by titration on TZM-bl (left) and PBMC (right). Infectivity per unit of
p24 capsid was calculated (RLU/ng p24) (S3 Fig) and data expressed as percent infection relative to the parental clone NAB01-PA. Data represent the
mean of two to three independent TZM-bl titrations, and the mean of three independent experiments on PBMC using different donor batches of three-way
stimulated PBMCs and freshly produced virus stocks. Error bars depict standard deviation (SD). (B) CD4low adapted viruses maintain infectivity during
cell-cell transmission. Env and NLinGluc cell-cell transmission reporter expressing 293-T were co-cultured with A3.01-CCR5 cells in the absence of
polycation to measure cell to cell transmission capability of the individual envelopes (S3 Fig) as described [95]. Data shown is the mean of two
independent assays, error bars are SD. (C) CD4low adapted viruses have high cell-fusion efficacy: Env and NL-Luc-AM reporter expressing 293-T cells
were co-cultured with rhesus Trim5α-expressing TZM-bl target cells to measure fusogenicity of panel envelopes. Data shown are the means of three
independent assays, error bars are SD. (D) CD4low adapted viruses are not prone to shedding of gp120. Gp120 shedding from Envelope-pseudoviruses in
response to treatment with the MPER nAb was assessed as the percentage of gp120 content after 2F5 treatment relative to mock-treated controls
normalized to p24 input. Data shown are the means of three independent assays, error bars are SD.
doi:10.1371/journal.ppat.1006255.g003
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for CD4low.c21 and CD4low.c24 (Fig 3A). Therefore, we probed the ability of the virus panel to
infect via cell-cell transmission (Fig 3B) and to undergo cell-cell fusion (Fig 3C). Cell-cell
transmission capacity was similar across the entire virus panel (Fig 3B). The control Env
PBMCcon.c14 proved to be the most efficient envelope in cell-cell transmission. Most impor-
tantly however, we detected no pronounced deficiency for the CD4low adapted strains CD4low.
c21 and CD4low.c24, which reached an average of 91% and 88% of the infectivity of
NAB01-PA, respectively. This suggested that cell-cell transmission may aid the virus to over-
come fitness deficiencies when altering receptor usage. Cell-fusion, however, portrayed an
entirely different picture (Fig 3C). The CD4low adapted clones CD4low.c21 and CD4low.c24
together with the control culture envelope PBMCcon.c14 were the most effective in initiating
fusion, reaching 267%, 253%, and 272% of NAB01-PA, respectively (Fig 3C). Thus, the free
virions of the CD4low adapted strains fail to efficiently infect despite intact, if not improved
fusogenicity of the Envs.
Decreased free virus infectivity of the CD4low adapted Envs could potentially indicate a low
stability of the Env trimers, i.e. trimers that are prone to shed gp120. While Env expressed on
the surface of an infected cell is continuously replenished by newly expressed Env, a low stabil-
ity would affect cell-cell transmission less than free virus infection, where Env on viral particles
degrades over time without active replacement. This would fit with the observed pattern of
retained cell-cell transmission and low free virus infection. We thus examined the propensity
of the Env panel to gp120 shedding in response to the MPER-specific bnAb 2F5, a potent
inducer of gp120 shedding [96]. While CD4 induced shedding would also be interesting to
define in the context of HIV-1 entry, the large differences in CD4 affinity of the panel nearing
a three-log variation in CD4 sensitivity (Fig 1) would not allow for a direct comparison of
effects. Measuring 2F5 induced gp120 shedding we observed a modest shedding activity
against the CD4low Env clones (27% and 42% for CD4low.c21 and CD4low.c24, respectively)
which was in the range of shedding observed for the parental (NAB01) and control (CD4low.
c14) envelopes (31% and 20%, respectively). Hence, a high propensity to gp120 shedding can-
not be underlying cause of the decreases free-virus infectivity of CD4low compared to parental
and control Env clones.
Adaptation to CD4low targets results in infectivity gain on macrophages
High affinity to CD4 has been associated previously with the capacity to infect cells expressing
low levels of CD4, in particular macrophages [18, 66, 78, 79, 97, 98]. To test macrophage infec-
tivity we produced two types of differentially conditioned monocyte derived macrophages
known to vary in CD4 and CCR5 expression [29], M-MDM have previously been shown to
express an average of 125 CD4 and 55 CCR5 receptors per cell while G-MDM have lower levels
of both receptors with an estimated 50 CD4 and 15 CCR5 per cell [29]. We verified the relative
CD4 expression on our cell preparations and indeed observed 3.1 fold lower CD4 levels on
G-MDM (S4 Fig).
As HIV-1 infection of MDM can show high donor variability we verified that the trend
observed in Fig 4 was maintained in eight donor cell batches (S4 Fig). Of note, absolute infec-
tivity of ultra-centrifuged Env pseudovirus on M-MDM normalized to p24 content of stocks
was close to what we observed for PBMC (S3 and S4 Figs). Overall, G-MDM infection was
markedly lower than M-MDM infection (27.4 fold lower NAB01-PA infection on G-MDM
than M-MDM; Fig 4A) in line with the lower expression of entry receptors on G-MDM cells.
Interestingly, free-virus infection of M-MDM with the CD4low adapted viruses yielded
infection levels closer to parental virus and controls on M-MDM (Fig 4A and 4B) than on
PBMC or TZM-bl (Fig 3A) with M-MDM infectivity of CD4low.c21 and CD4low.c24 being
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only 2.6 and 3.0 fold lower compared to NAB01-PA on, respectively (Fig 4B). The pattern of
G-MDM infection was strikingly different. While absolute G-MDM infection was generally
lower for all probed viruses (Fig 4A), the CD4low clones infected G-MDM with higher effi-
ciency than the parental and culture control viruses (2.5 fold and 4.9 fold higher compared to
NAB01-PA, respectively; Fig 4B). CD4low.c21 and CD4low.c24 reached 23.9% and 58.5%,
respectively, of M-MDM infection levels on G-MDM (Fig 4C). In contrast, the parental clone
NAB01 showed only 2.7% infectivity on G-MDM compared to M-MDM, similar to
NAB01-PA and PBMCcon.c14 (3.6% and 2.2%, respectively). Infection of both M-MDM and
G-MDM again emphasized the contrasting phenotypes of the two reversion clones. CD4low.
c21-rev was the least and CD4low.c24-rev one of the most effective of the entire panel in infec-
tion of both MDM subtypes. In sum, the differential infectivity of macrophage subtypes across
virus strains supported the observations made using the Affinofile system. Differential macro-
phage infections further highlighted that adaptation to usage of low CD4 levels can optimize
infection of specific cell subsets and thus needs to be considered as an important parameter in
shaping target cell tropism throughout disease progression.
Fig 4. Adaptation to CD4low allows efficient infection of macrophages. (A) Two types of macrophages, M-MDM and G-MDM expressing
differential CD4 levels (S4A Fig) were infected with 0.1ng p24 of ultra-centrifuged Env-pseudotyped luciferase reporter virus stocks infection
measured on day seven post-infection by quantifying luciferase reporter activity (relative light units (RLU)). Data are means from two individual
donors, input of ultracentrifugation purified virus was standardized by p24 content, error bars = SD. (B) Infection of M-MDM and G-MDM by CD4low
adapted viruses relative NAB01-PA (data derived from A. (C) Comparison of M-MDM and G-MDM infectivity. Shown is the relative infectivity of
G-MDM compared to M-MDM infection (data derived from A).
doi:10.1371/journal.ppat.1006255.g004
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Adaptation to low CD4 levels gives rise to envelope mutations
associated with macrophage tropism
We next explored the sequence alterations that occurred during adaptation to CD4low pressure
(Fig 5 and S4 Table). Locating globally relevant sites of macrophage tropism determination
has proven difficult [21]. Numerous mutations have been associated with macrophage tropism
Fig 5. Gp120 sequence mutation pattern following adaptation to CD4low targets. (A) Summary of amino acid mutations acquired as a result of
adaptation to long term in vitro culture and adaptation to CD4low. Green shading indicates mutations affecting N-linked glycosylation sites. Red boxes
denote mutations that occur in both CD4low adapted clones, yellow and orange boxes indicate mutations that occurred only in CD4low.c21 and CD4low.c24,
respectively. (B) Structural representations of mutated residues in NAB01 associated with adaptation to low levels of CD4 mapped onto crystal structure
5fyj of X1193.c2 SOSIP [100]. Dark gray residue shading indicates limits of non-resolved region of gp120 V4 loop. Missing from the model are the residue
at 402, within the non-resolved region of V4, and the glycans at residues 408 and 461 which are not present on this subtype G Env variant. Structure
rendered using PyMol version 1.4.1 [101].
doi:10.1371/journal.ppat.1006255.g005
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but were largely found to be strain-specific. Of note, the parental virus NAB01 and all variants
derived through culturing lack E153G, T283N, or N386D signatures of enhanced macrophage
tropism (reviewed in [14]). CD4low adaptation resulted in five mutations in gp120 common to
both CD4low.c21 and CD4low.c24 clones (Fig 5A and S4 Table). The five mutations observed in
CD4low Envs include I165K in the V2-loop, F317L in the V3 loop, and in the V5 region a dual
deletion at G459 and G460 in combination with N461D that eliminates a potential N-linked
glycan at position 461 in the CD4 contact site in V5 [99]. The location of the mutated residues
is highlighted on the crystal structure model of subtype G Env trimer X1193.c2 [100] as this
structure provides a high resolution of the V4 region (Fig 5B). Although this Env is missing
glycans that we found to be under selection pressure in our adapted viruses, overall mapping
of the mutated residues onto the X1193.c2 structure provided interesting insights on their
approximate spatial distribution.
V2 loop. The mutation I165K is located within the V2 loop in the trimer association area
at the apex of the trimer (Fig 5B) and is present in only 0.04% of 4907 envelope sequences ana-
lyzed from the Los Alamos Database (S5 Fig). The sequences in this database are dominated
by virus derived from plasma and PBMC, and thus are less likely to capture frequencies
amongst macrophage or CNS replicating viruses. However, the I165K mutation is found in
only 1 of the 98 patients with subtype B Env sequences with CNS ontology included in the
HIVbrainseqDB [102], further suggesting that this mutation is rare. In addition to I165K, the
V1V2 net charge increased upon adaptation to PBMC from -0.2 to +0.8 and further to +1.8
upon CD4low adaptation. This level of V1V2 charge was sustained for both reversion clones
(S4 Table).
V3 loop. No overall net changes in charge of the V3 were observed (S4 Table). The
V3-loop mutation F317L that emerged in the CD4low clones is also rare (0.14% of the Los Ala-
mos HIV sequences, 0.06% of subtype B; S5 Fig). F317L has previously been associated with
the CD4low adaptation of CNS-derived envelopes [79], and is also prevalent in 14 of 98 patients
with CNS derived Subtype B viruses from the HIVbrainseqDB [102]. Residue 317 is located
within the highly conserved hydrophobic tip of the V3 loop and has previously been associated
with heterodimer stability [103].
CD4bs. The CD4low adapted envelopes shared three mutations proximal to the CD4bs;
two deletions in the V5 (G459del, and G460del) and an N461D mutation which eliminates a
highly conserved N-linked glycosylation site (found in 99.86% of 4907 sequences in the Los
Alamos Database) (S5 Fig). Of the three mutations that the CD4low envelopes shared, N461D
was the only one which reverted upon passaging on PBMC with normal CD4 levels in one of
the isolated reversion clones (CD4low.c24-rev).
N-glycosylation sites. Both CD4low clones lost further glycosylation sites present in the
parental strain (Fig 5A). Mutations T402P, T408N, and T412N present in CD4low.c21 and
CD4low.c21-rev are located in a highly variable domain of the V4. These mutations resulted in
loss of glycans at positions 402 and 409, and a transfer of an N-linked glycosylation site from
406 to 408. Removal of glycans at 410–412 has been reported to decrease infectivity and
increase the potential of the envelope to generate neutralizing antibodies, presumably by
exposing neutralization sensitive epitopes [104]. Likewise, N197D, present in both CD4low.c24
and CD4low.c24-rev, destroys a potential N-linked glycosylation site at the apex of the trimer
spike known to modulate sensitivity to CD4bs nAbs [105], cause increased CCR5 binding
[106, 107] and, in combination with V/T200 (found in all the NAB01 derived clones), has been
associated with macrophage tropism in the CNS [108].
Interestingly, by acquiring a L856Q mutation the CD4low adapted clones loose the gp41 C-
terminal di-leucine internalization motif thought to play a role in reducing Env content from
infected cell surface membranes [109].
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High affinity to CD4 is associated with prolonged transitioning during
entry from CD4-bound stage to CCR5 engagement and fusion
Altered conformational transitions of the trimer upon receptor engagement have been sug-
gested as an attribute of macrophage-tropic envelopes able to use low levels of CD4 [98]. Con-
sidering their increased ability to accomplish membrane fusion (Fig 3C) and to utilize low
levels of CD4 to infect (Figs 2A, 2C and 4), we hypothesized that CD4low adaptation may have
an influence on the kinetics of attachment and entry.
To assess the relative timing of transitions between the three key steps in the entry process
—CD4 engagement, coreceptor binding and fusion—we employed a time-course inhibitor
addition experiment with inhibitors targeting CD4 (CD4-DARPin 55.2), CCR5 (maraviroc)
and HIV-1 fusion (T-20) (Fig 6A). In this assay setup, synchronized infection is achieved
through spinoculation at 4˚C (a temperature which prevents receptor engagement) and a shift
to 37˚C post-spinoculation to initiate entry. Saturating concentrations of inhibitors were
added to replicate infection wells at progressive time points from the initiation of infection (0
min) up to 120 min post infection (Fig 6A). For each inhibitor, we considered the relative
infectivity compared to the 120 min post infection value and fitted infection curves to estimate
the time required by each virus to reach 50% of entry level reached by the 120 min treatment
point (Fig 6B).
When comparing the kinetic of the parental NAB01 virus with the two CD4low adapted
clones, we observed a striking difference of the times needed to transition from the CD4
bound to the CCR5 bound state as well as from CCR5-to-Fusion (Fig 6C). Whereas the time
required to reach 50% fusion differed only 1.4-fold across all eight panel viruses (36.3–50.3
minutes post infection), the time required to complete 50% CD4 binding and 50% CCR5
engagement differed markedly. Most strikingly, we found that the CD4low adapted envelopes,
though they engaged CD4 rapidly, required a significant increase in time for the transition
between CD4 binding and CCR5 engagement (Mann-Whitney test, p = 0.00003 and 0.00024
for comparison between NAB01 and CD4low.c21, NAB01 and CD4low.c24, respectively). While
time windows for CD4 and CCR5 binding tightly overlapped for NAB01 and the derived
PBMC adapted strains, suggesting a very rapid transition between CD4 and CCR5 engagement
for these strains, the CD4low.c21 and CD4low.c24 strains had a time window of 33.2 and 19.6
min between CD4 and CCR5 engagement, respectively. This gap proved largely due to a very
rapid initial engagement of CD4 (Fig 6D) and not a postponing of CCR5 binding. In line with
their high affinity for CD4, the CD4low adapted envelopes already established a firm CD4 bind-
ing during the 30 minute spinoculation at 4˚C, reaching a mean of> 40% of the maximal
infection (CD4low.c21 at 47.4% and CD4low.c24 at 42.4%; Fig 6C). This was in striking contrast
to the rest of the NAB01 virus panel that only reached infection levels between 2.7% and 8.5%
before initiation of the entry process by shifting cultures to 37˚C. Interestingly, rapid CD4
binding appeared to be an unfavorable trait that the virus only maintained under selection
pressure likely as it requires a more open conformation of the trimer. Both reversion clones
increased the time to CD4 engagement, and consequently shortened the CD4 to CCR5 transi-
tion window.
We then asked whether the phenotype we observed in the CD4low envelope clones could
potentially be found in vivo, particularly in the CNS where the immune pressure by neutral-
izing antibodies is less active. To address this question we probed the entry kinetics of a
panel of three well established macrophage-tropic envelopes from the CNS (B33 and B59),
and plasma (C98-15) together with patient-matched non-macrophage-tropic Envs from
lymph nodes (LN40, LN8), and plasma (C98-27) (S5 Table) [64, 76–79]. The rapid engage-
ment of CD4 exhibited by the CD4low Envs was reproduced by the macrophage-tropic
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Fig 6. CD4low adapted viruses need extended time to transition between steps in the entry process. (A) Schematic of entry kinetic assay to
measure timing of CD4 binding, CCR5 binding, and fusion. Virus is added to TZM-bl in the presence of the polycation DEAE, spinoculated onto cells
at 2095g for 30 min at 4˚C to limit conformational changes upon CD4 binding. Infection is synchronized by the addition of warmed media and
inhibitors targeting CD4 (DARPin 55.2), CCR5 (Maraviroc), and fusion (T-20) added in saturating concentrations at 0, 5, 10, 15, 20, 30, 45, 60, and
120 min post start of infection. (B) For each envelope, one representative time course of infection is shown. Infectivity data are normalized to
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envelopes (Fig 7A and 7C). The time to CD4 binding for all three patient pairs (B33/LN40,
B59/LN8, C98-15/ C98-27) shows a trend of faster CD4 engagement by the macrophage-
tropic envelopes when compared to their non-macrophage-tropic paired Env (Fig 7B),
though this difference achieves statistical significance only between B33 and LN40 (Fig 7D).
Of all patient derived envelopes, the brain-derived B33 also displays the longest CD4 to
CCR5 transition (Fig 7B and 7D). The phenotype we observed for CD4low Envs may there-
fore occur in vivo, and in particular in the CNS, where antibody pressure is commonly
reduced compared to other compartments. All transitions of the entry process were signifi-
cantly different between the CD4low clones and NAB01, except time from start to fusion (Fig
7D, Mann-Whitney test). The trends highlighted by the more extreme phenotype of the
CD4low envelopes were displayed most similarly by B33, and by B59 and C98-15 to a lesser
degree (Fig 7D). To test the sensitivity of our analysis method, we estimated T½ values in
additional ways. First, we averaged the data points from all replicates, prior to fitting only
one curve, and since two replicates were always conducted within the same experiment, we
also pooled these two data points before fitting the curves and averaging individual T½ val-
ues. Whenever taking the average, we also considered using the median instead of the mean.
These different data treatment and analysis methods mostly decreased the power to detect
significant differences (S6 Fig), however they had only a minor impact on estimated parame-
ters (S7 Table) and subsequently the trends observed between macrophage-tropic/CD4low
compared to non-macrophage-tropic/NAB01 were reproducible.
We further profiled the patient paired macrophage-tropic and non-tropic Env functionality
in free-virus infectivity, cell-cell transmission, and cell-fusion to determine the depth of phe-
notypic similarity shared between CNS-macrophage tropic and CD4low Envs. Interestingly,
the infectivity of the CNS-derived macrophage-tropic B33 and B59, but not the plasma-derived
C98-15 macrophage-tropic Env was increased relative to their respective non-macrophage
tropic control Envs (Fig 8A). The lymph-node derived LN40 and LN8 reached only 12% and
18% of B33 and B59’s free-virus infectivity, while C98-15 had half the infectivity of the non-
macrophage tropic variant C98-27 (205%). A similar trend was observed in cell-cell transmis-
sion where LN40 and LN8 reached 3.5% and 16.5% of the cell-cell capacity of B33 and B59,
respectively (Fig 8B). The capacity of all three macrophage-tropic Envs to initiate cell-fusion
was similar to the controls, ranging from 98% to 150%, relative to non-macrophage tropic (Fig
8C). Of particular note, all three macrophage-tropic Envs showed an increase in gp120 shed-
ding relative to their paired non-macrophage-tropic Envs, regardless of the tissue of origin
(Fig 8D). Both B33 (57%) and B59 (61%) lost more than twice as much gp120 as LN40 (20%)
and LN8 (25%). The plasma-derived Envs were more similar, showing 77% and 52% gp120
shedding for C98-15 and C98-27, respectively.
Prolonged transitioning to CCR5 engagement coincides with increased
vulnerability to V3 loop and CD4i directed antibodies
We next examined the sensitivity of the virus panel to entry inhibitors and neutralizing anti-
bodies (nAbs) targeting diverse regions of the envelope (S1 Table) to elucidate the conse-
quences of adaptation to low levels of CD4 for shielding and the susceptibility to neutralizing
infection at 120min post infection and all treatment conditions are shown as relative infectivity compared to this 100% level. (C) Definition of transition
times required to reach 50% of transition to CD4 bound, CCR5 bound stage and fusion. For each inhibitor and each of at least eight replicate
measurements derived from four to six independent experiments, T½ values of infection times were estimated. The mean of these estimates is a
proxy for the time required to reach 50% CD4 resistance, 50% CCR5 resistance, and 50% fusion resistance. Error bars denote SD. (D) Percentage
of viruses already resistant to CD4 blocking following the 30 minute spinoculation at 4˚C. Data points are derived from four to six independent
experiments done in replicates. Horizontal bars depict means.
doi:10.1371/journal.ppat.1006255.g006
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Fig 7. CNS-derived Macrophage-tropic viruses show similar entry pattern with rapid engagement of CD4. (A) to (C) Times to reach
50% resistance to CD4, 50% CCR5, and fusion inhibitors was determined for the shown pairs of patient derived macrophage-tropic and non-
macrophage-tropic viruses as described in Fig 6B to 6D. Data for each inhibitor and virus combination were derived from at least eight
replicates from four to six independent experiments. (A) For each envelope, one representative time course of infection is shown, normalized
to infection at 120min post infection. Data shown is for a replicate representative of the calculated mean of all replicates. (B) Time intervals
between four stages of the entry process (synchronized start, CD4 binding, CCR5 attachment, fusion) were compared by Mann-Whitney tests
of NAB01 and CD4low viruses and M-tropic and non-M tropic pairs from the analyzed three patients. Only envelopes from the same patient
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antibodies. Analysis of the sensitivity of free virus infection to anti-CD4 and CCR5 receptor
agents using NAB01-PA as the point of reference highlighted that a modest decrease in sensi-
tivity to CD4 inhibition in the CD4low strains was mirrored by an equally modest increase in
sensitivity to the CCR5 inhibitors (Fig 9A and S6 Table). This agrees with the higher
(same principal color) were compared. (C) Data depict the percent of virus already resistant to CD4 blocking following the 30min spinoculation
at 4˚C. Individual data points are two replicates from each of four to six independent experiments. Horizontal bars depict means. (D) Statistical
analysis of entry kinetics. Data points from four to six individual experiments were combined before fitting the curves and averaging individual
T½ values. Estimated time intervals between the four stages of the entry process (synchronized start, CD4 binding, CCR5 attachment, fusion)
were compared by Mann-Whitney tests. Only envelopes from the same patient (same principal color) were compared. Alternate statistical
analysis using paired replicates before curve fitting shown in S6 Fig.
doi:10.1371/journal.ppat.1006255.g007
Fig 8. CNS-derived Macrophage-tropic viruses show increased infection capacity and gp120 shedding. (A) Cell-free
virus infectivity is increased in CNS-derived macrophage tropic Envs. Infectivity of Env-pseudotyped cell-free virus stocks was
assessed by titration on TZM-bl. Infectivity per unit of p24 capsid was calculated (RLU/ng p24) (S7 Fig) and data expressed as
percent infection relative to the patient-paired non-macrophage-tropic Env. Data shown is the mean of two independent assays,
error bars are SD. (B) CNS-derived macrophage-tropic Envs have improved infectivity during cell-cell transmission. Env and
NLinGluc cell-cell transmission reporter expressing 293-T were co-cultured with A3.01-CCR5 cells in the absence of polycation
to measure cell to cell transmission capability of the individual envelopes (S7 Fig) as described [95]. Data shown is the mean of
two independent assays, error bars are SD. (C) CNS-derived macrophage-tropic Envs maintain similar cell-fusion efficacy to
non-macrophage tropic Envs: Env and NL-Luc-AM reporter expressing 293-T cells were co-cultured with rhesus Trim5α-
expressing TZM-bl target cells to measure fusogenicity of panel envelopes. Data shown is the mean of two independent assays,
error bars are SD. (D) CNS-derived macrophage-tropic viruses have increased shedding of gp120. Envelope-pseudoviruses
carrying mouse CD4 were treated with 2F5 to induce gp120 shedding and immobilized using magnetic beads. Shed gp120 and
non-bound virus was washed away and gp120 and p24 levels measured by ELISA as described [96]. The difference between
gp120 levels of 2F5 treated and to mock-treated controls is depicted as % gp120 shed. Data shown are the means of three
independent assays, error bars are SD.
doi:10.1371/journal.ppat.1006255.g008
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dependency on CCR5 observed in the Affinofile analysis for the CD4low Envs (Fig 2 and S1
and S2 Figs) and was also supported by the observation that the reversion clones lost CCR5
inhibitor sensitivity while regaining sensitivity to CD4 inhibition. Interestingly, the CD4low
strains portrayed a much higher resistance to CD4 inhibition during cell-cell fusion while sen-
sitivity to CCR5 inhibition showed no alteration (Fig 9B).
Adaptation of primary isolates to growth in vitro in the absence of neutralizing antibody
pressure commonly leads to the emergence of virus variants with increased neutralization sen-
sitivity [87]. This was also true for the PBMC long-term cultured NAB01-PA, which displayed
higher sensitivity to chronic patient plasma from 24 individuals with chronic HIV-1 infection
(eleven subtype B, four subtype A, and three of each subtype C, 01_AE, and 02_AG) (Fig 9C),
and nAbs targeting V3, CD4bs, and CD4i (Fig 9D) than the parental NAB01. Sensitivity to V3
glycan and MPER nAbs, and the fusion inhibitor T-20 did not differ between NAB01 and
NAB01-PA. In contrast, the V2 glycan nAb PGT145, which depends on a closed trimer con-
formation for neutralization, showed a 2.7-fold reduced activity against NAB01-PA. CD4low
adaptation amplified this phenotype and resulted in a substantial increase in neutralization
Fig 9. CD4low adapted envelopes show heightened sensitivity to inhibitors targeting the CD4bs, V3 loop, and CD4i epitopes, and patient
plasma. (A) and (B) Sensitivity of the CD4low viruses to inhibitors of CD4 (DARPin 55.2) and CCR5 (PSC RANTES, Pro140, Maraviroc). IC50 values are
shown relative to the IC50 of NAB01-PA in (A) free virus entry on TZM-bl and (B) 293T-TZMblTRIM5α cell fusion. Individual IC50 values are listed in S6
Table. (C) Sensitivity of CD4low virus panel to heterologous plasma neutralization. Data are medians derived from neutralization titer on TZM-bl cells of
patient plasmas from 24 individuals with different HIV-1 subtype chronic infections (eleven subtype B, four subtype A, and three of each subtype C,
01_AE, and 02_AG). (D) Sensitivity of CD4low virus panel to neutralizing antibodies and Env targeting inhibitors (S1 Table). IC50 values were derived in a
standard pseudovirus neutralization assay on TZM-bl cells. Darker shading indicates higher sensitivity. Data shown in A, B, and D are mean values from at
least two independent assays for each inhibitor.
doi:10.1371/journal.ppat.1006255.g009
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sensitivity to nAbs targeting the CD4bs, CD4i, and V3 epitopes, as well as patient plasma (Fig
9C and 9D), ranging from 446-fold (for nAb b6) to 4301-fold (for nAb 447-52d). The V3 tar-
geting DARPin D12 [110], which recognizes the V3 loop in a structure-dependent manner,
slightly decreased in activity against the CD4low and reversion strains compared to
NAB01-PA. Similarly, the conformational epitope of PG145 was lost completely in the CD4low
envelopes, and was not restored in the reversion clones. Reversion culture viruses also only
showed a partial recovery of resistance to V3 and CD4bs nAbs.
Influence of CD4low adaptation on entry stoichiometry
Considering the substantial changes in neutralization sensitivity, entry kinetics, and infectivity
across the virus panel, we were next interested to explore if the stoichiometry of entry is
altered. It is plausible that the Env conformations which favor CD4 binding that are induced
by in vitro culture in the absence of neutralization pressure, and adaptation to low levels of
CD4 are associated with energetic losses, and in consequence may need more trimers to com-
plete entry [111–113]. To test this, we generated dominant negative Env mutants by introduc-
ing R508S/R511S (SEKS) to all panel viruses to knock out the furin-like protease cleavage site
between gp120 and gp41, as described [112]. Mixed trimer virus preparations with SEKS vari-
ants in varying ratios with wild-type Env were generated and analyzed for infectivity (Fig
10A). Using this data and the average number of trimers per virus particle that was determined
in parallel (Fig 10B and S8 Table) allowed us to estimate the minimal number of trimers
required for viral entry (T) using a previously established mathematical model [111–113].
While the primary virus NAB01 required only one trimer for entry (T = 1), adaptation to
PBMC in vitro culture caused an increase of minimal number of trimers required for entry
ranging from T = 2 to T = 4. CD4low adaptation maintained T = 4, underlining a continued
need for more trimers to be employed in the entry process for these virus variants. The two
CD4low reversion clones showed a substantial decrease in the average trimer number per
virion, decreasing by 3.7- and 2.8- fold for CD4low.c21-rev and CD4low.c24-rev from their
parental clones, respectively. For CD4low.c21-rev this was particularly striking as the average
number of trimers per virion (2.1) was lower than the estimated number of trimers required
for entry (T = 5). Thus only a small fraction of CD4low.c21-rev virions will carry the required
number of trimers necessary to facilitate entry (Fig 10D) and this provides a potential explana-
tion for the particularly low infectivity observed across cell types for (Figs 3A and 4B).
Discussion
During disease progression HIV-1 must overcome the decreasing supply of activated CD4+ T
cells, which express high levels of CD4 and the CCR5 coreceptor [10, 35, 115, 116]. The transi-
tion of the virus to altered receptor usage and the ensuing changes in cell tropism at later dis-
ease stages have been extensively studied over the past 30 years, yet many details remain
elusive [14, 20, 36, 65, 69–71, 117–120]. The observed transitions during the course of the
infection are thought to be needed to allow the virus to infect a broader range of host cells.
This may require altered coreceptor usage [15, 77, 121], or modifications to allow infection of
cells that express lower CD4 levels. Low CD4 usage in particular is exemplified by R5 viruses
exhibiting macrophage tropism [63, 65–67, 74, 77, 78, 98, 122–124]. Development of increased
CD4 binding capacity by gp120 has been implicated in high macrophage tropism [125–127],
which may have relevant consequences in disease progression (reviewed [128]), however the
forces that lead to this phenotype have not been clearly defined. One clue has been provided
by the frequent association of highly macrophage-tropic envelopes with CNS infection in late
disease [129] suggesting features of this compartment particularly favor or facilitate the
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development of envelopes with high CD4 affinity. Adaptation of the HIV-1 envelope to
CD4low conditions warrants study to elucidate potential intermediate evolutionary states,
CD4low associated phenotypes, and to improve our understanding of the forces driving devel-
opment of this niche phenotype at the high end of the continuum of CD4 use.
In the current study we adapted an R5-tropic HIV-1 envelope, isolated from a chronic
patient, to CD4low conditions on PBMC in vitro. Our setup mimicked the environment that is
thought to occur in early infection and the CNS compartment, which is with little or no neu-
tralizing antibody pressure. The ensuing CD4low adapted envelopes displayed a very high affin-
ity binding to CD4. Altered CD4 affinity specifically opens transmission to a new population
Fig 10. Envelopes adapted to low levels of CD4 require a higher proportion of their available trimers to complete
entry. (A) Relative infectivity of mixed trimer infection experiments with CD4low panel viruses using the R508S/R511S
dominant-negative Env mutants. Infectivity of pseudotyped virus stocks expressing the indicated ratios of wild type and
dominant-negative mutant Envs was measured on TZM-bl reporter cells. Infectivity of virus stocks containing solely the
respective WT envelope were set as 100%. Data depict mean from two independent experiments. (B) Experimentally defined
mean trimer number per virion measured from four independent assays (S8 Table) were used to derive mathematical
estimates of the entry stoichiometry T based on data shown in (A) as described [112]. (C) Graphical presentation of mean
trimer number per virion and estimated stoichiometry of entry as shown in (B). (D) The percentage of infectious virions, i.e.
virions with at least T trimers, was calculated for each single viral variant based on trimer numbers distributed according to a
discretized B-distribution with the measured mean (Fig 10B) as described in [114].
doi:10.1371/journal.ppat.1006255.g010
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of cells via an amplified ability to use low amounts of CD4 on the target cells. While these char-
acteristics suggest an overall benefit to CD4low adaptation, we lay out here that this comes at
severe costs for the virus in terms of general infectivity and vulnerability to neutralization.
Adaptation of the NAB01 parental WT envelope to in vitro PBMC infection resulted in the
S190R and V84I mutations. Herschhorn and colleagues have recently described the impact of
mutating the highly conserved leucine at position 190 in the V2 loop [130]. Replacing the L
with either an alanine or arginine provided JR-FL (subtype B) and BG505 (subtype A) with
improved macrophage infection, increased sensitivity to CD4 binding, and higher neutraliza-
tion sensitivity by non-neutralizing Abs. Their evidence suggests the mutations enrich the
amount of envelopes present in a functional state between the ‘closed’ wild-type conformation
and the CD4-bound ‘open’ conformation. While NAB01-PA only showed slightly improved
macrophage infection, sensitivity to non-neutralizing Abs 1–79, 447-52d, 17b, and b6 were
markedly increased, in agreement with an enrichment of the in-between state of envelope
conformation.
CD4low adaptation in the NAB01 envelope background occurred by the removal of several
structural elements that presumably relaxed restrictions of access for both CD4 and CD4bs
specific nAbs. Particularly notable were a deletion of glycosylation sites and part of the V5
loop (affecting residues 459–461) projecting into the space leading to the CD4bs (Fig 5B) [99].
While these changes were linked with an increased ability to bind CD4, the loss of shielding
resulted in increased accessibility for CD4bs and CD4i nAbs that are normally well shielded
off as exemplified by the increase in efficacy of the CD4bs mAb b6 and the CD4i mAb 17b (Fig
9D). Addition of a positive charge at residue I165K, which comes into close proximity with the
neighboring subunits at the trimer association region, has the potential to reduce shielding, by
disrupting the interplay of the neighboring V1V2 regions. Mutation of the conserved F317 res-
idue in the V3 is linked with decreased association of gp120 and gp41 [103], further suggesting
a decreased conformational stability for the Envs adapted to CD4low.
Our detailed analysis of CD4low envelope entry kinetics further supports a reduction in the
energy provided by conformational rearrangements during the multi-step entry process. Fol-
lowing a very rapid CD4 engagement, the time required to transition between steps in the
entry process is significantly extended for CD4low adapted envelopes (Figs 6 and 7 and S6 Fig),
yet interestingly, the overall length of entry remained comparable. The delay within entry
occurs most drastically between binding of CD4 and attachment to CCR5 in the CD4low
clones. Given the ability of CD4low Envs to bind to CD4 rapidly and at temperatures normally
restrictive to conformational changes, it is surprising that CCR5 attachment does not proceed
any quicker, indicating that the CD4low viruses depend on the CCR5 interaction to release the
required amount of energy to progression to the next stage of entry. We speculated this may
relate to a decreased potential energy carried within the open conformation of the trimers, and
could prospectively impact entry stoichiometry. A requirement for a larger number of trimers
in order to overcome opposing membrane potentials during entry could help explain the
observed delay between CD4 and CCR5 binding. However, the T (stoichiometry of entry) val-
ues estimated for CD4low envelopes were comparable to the non-CD4low envelopes adapted to
in vitro culture, both types requiring four trimers for entry. Notably, the CD4low adapted
clones showed a higher T paired with lower overall trimer content on virions. Thus a large
fraction of viruses in these populations will not carry the minimal amount of trimers necessary
for entry and a high proportion of the available trimers needs to be engaged in the entry pro-
cess to make infection possible likely explaining the low infectability of these viruses. Whether
the CD4low viruses have a CD4 bound conformation that differs from wild type requiring lon-
ger to interact with CCR5 or whether this indicates that more CCR5 receptor interactions per
trimer have to occur will be further interesting possibilities to explore in future studies.
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The in vitro adaptation to CD4low targets generated envelope variants with the likely benefi-
cial phenotype of expanded cellular and receptor tropism and drastically increased CD4 bind-
ing. However, as mentioned above, the beneficial phenotype comes at the cost of reduced
infectivity (Fig 3 and S3 Fig), extended exposure of neutralization sensitive epitopes during
entry (Figs 6 and 7), and increased neutralization sensitivity (Fig 9C and 9D). Partial reversion
of these phenotypes after readapting to CD4high conditions indicates that an increase in CD4
binding affinity may result in an ultimately less-fit envelope.
The CD4low envelopes proved generally neutralization sensitive in line with the reduced
shielding and a prolonged exposure of neutralization sensitive epitopes during entry. It may
therefore be critical for this phenotype to develop away from the pressure provided by nAbs in
vivo. Our examination of CD4low linked phenotypes suggests possible mechanisms that could
support development of the neutralization sensitive phenotype. One avenue of adaptation is
suggested by our finding that free virus infectivity is dampened for CD4low envelopes but their
ability to disseminate via cell-cell transmission is comparable to the primary isolated Env (Fig
3). Maintenance of the cell-cell pathway could potentially serve as a rescue mode of viral trans-
mission supporting previous observations [95, 131, 132]. Cell-cell transmission could thereby
allow transmission of less fit virus while adaptation passes through neutralization sensitive
intermediates on the way to a more optimally fit phenotype adapted to a CD4low environment.
The in vitro passaging protocol used in this study is expected to encourage the selection of
Envs competent in free-virus infection. Passaging was performed for 16 of the 18 weeks with
virus supernatant only. The observed conservation of cell-cell capacity in the face of cell-free
selective pressure suggests either a strong impetus to maintain this phenotype, or a lack of
effect of the CD4low adaptation and passaging on the cell-cell phenotype. In addition, we
expect that the absence of neutralization pressure during in vitro passaging allowed the rever-
sion Envs CD4low.c21-rev and CD4low.c24-rev remaining sensitive to neutralization.
In the cell-cell experiment we used one T cell line, A3.01-CCR5 [131], as targets which, as
all T cells, has high CD4 levels and is thus comparable to TZM-bl cells in respect to CD4
expression. However, while our data show that a large variation exists in the CD4 use and
infectivity of our envelope panel (Figs 1C–1E, 2, 3A and 4), the cell-cell transmission shows lit-
tle to no difference across the panel. While we cannot rule out that differences in cell-cell trans-
mission may occur when target cells with lower levels of CD4 are involved, in a comparison of
CD4high expressing targets only free virus transmission was affected.
In conjunction with competency in cell-cell transmission, the fusion capacity of CD4low
envelopes is 2-fold higher than that of NAB01, which may pose a problem to the development
of CD4low use in vivo. Primarily, cell-fusion does not lead to productive infection and syncytia
resulting from cell-fusion may not be long-lived [133]. Therefore, increased fusion in combi-
nation with higher CD4 use could result in a dead end path for the virus and thus be a further
reason why the virus rarely opts for high CD4 affinity in vivo.
The extreme CD4low phenotype was lost during re-adaptation to high CD4 expressing tar-
gets even in the absence of nAb pressure. Adaptation to CD4low may therefore encounter resis-
tance from the various fitness related requirements of virus replication in vivo. This is
supported by the establishment of novel infections by non-macrophage-tropic R5 envelopes
[134] due to the fitness costs associated with CD4low use described here, and the bottleneck at
transmission selecting high-fitness variants in newly established infections [135]. We have
addressed the question of how CD4low envelopes might develop in vivo by comparing the
entry phenotypes with those of well-defined CD4low using envelopes isolated from patients to
find that the CD4low phenotype can be recapitulated amongst viruses replicating in the CNS. It
is intriguing that one of the CNS derived envelopes (B33) displayed a phenotype similar to the
CD4low adapted clones 21 and 24, while the other (B59) did not. A potential explanation for
Delineating CD4 dependency of HIV-1
PLOS Pathogens | DOI:10.1371/journal.ppat.1006255 March 6, 2017 22 / 42
this discrepancy could be that B33 and B59 were isolated from CNS at different stages of CNS
infection [136] and/or replicated within different cell types [93]. An additional non-competing
possibility is that the status of the blood-brain-barrier is affected by the progression of infec-
tion [137] differentially in the respective patients, hence allowing more neutralizing antibodies,
and/or plasma derived viruses to traverse to the CNS in certain patients. Of the five shared
mutations found in both CD4low clones (Fig 5), the only one shared by one of the CNS derived
envelopes is 317L which is also found in B33 and has been associated with the ability to use
low levels of CD4 [79].
The phenotypic characterization of the CNS-derived macrophage-tropic Envs highlights
similarities (e.g. similar entry kinetics) but also differences to our CD4low adapted Envs sug-
gesting that our in vitro adapted clones represent an intermediate evolutionary phase with
reduced cell-free infectivity. The CNS-derived macrophage-tropic Envs, which displayed
superior infectivity in cell-free and cell-cell transmission modes relative to their paired con-
trols (Fig 8), may have passed this stage and acquired compensatory mutations that preserve
the entry phenotype but restore infectivity. In particular the elevated infection competency
of these CNS-derived Envs despite increased gp120 shedding suggests these Envs have
undergone severe selective refinement in vivo during their development. It is tempting to
speculate that cell-cell transmission in vivo may have supported the evolution of these shed-
ding-prone, yet highly infecting competent envelopes. While our in vitro selection favored
free transmission as only supernatant was passaged, in vivo both transmission pathways will
be available.
Though the CNS was once considered a site of immunological privilege, it has been estab-
lished that various branches of the immune system operate within the CNS [138–140] includ-
ing the production of limited amounts of antibodies from within the cerebrospinal fluid [141].
Envelopes evolving within the CNS may therefore encounter some humoral immune pressure,
as B59 may have, though the impact of such an interaction on envelope evolution remains an
open question. The lack of an extended entry phenotype in C98-15, isolated originally from
plasma, further shows that the phenotype observed is not a universal feature of all highly mac-
rophage-tropic envelopes and may potentially differ depending on whether the clone recently
evolved or was circulating (and adapting) for an extended period of time. Nevertheless, the
overall trend within each pair of macrophage-tropic and non-macrophage-tropic envelopes
mirrors the difference between CD4low adapted and non-adapted Envs from our panel includ-
ing an increased speed of CD4 binding and extension of transition steps (Fig 7D).
Arrildt and colleagues [125] recently conducted an interesting profiling of phenotypes of
primary macrophage-tropic isolates. They found that macrophage-tropic primary isolates
were not significantly different from matched control Envs in a variety of functional charac-
teristics including infectivity and entry kinetics, as well as neutralization sensitivity to
plasma and V1V2 targeting nAbs. Proposed evolutionary intermediate Envs accordingly
showed a moderate sensitivity to CD4. In contrast our CD4low Envs and the CNS-derived
macrophage tropic Envs differ from their patient-matched controls. As our Envs, like the
CNS-derived macrophage tropic Envs, have not been exposed to humoral immunity during
adaptation, it is tempting to speculate that they represent an early adaptive stage that could
develop only where humoral immunity is low as in sanctuary sites as the CNS. Infectivity
defects, as the CNS derived strains highlight, need not to be associated with this phenotype
of CD4low usage and likely are only a transition point in the evolution towards a stable and
fit variant.
In summary, adaptation to low levels of CD4 on target cells appears to occur in direct oppo-
sition to nAb escape, providing a plausible explanation for the association of highly macro-
phage-tropic envelopes with the CNS and their appearance before nAb development [80].
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Inhibition of the gp120 and CD4 interaction using reagents that bind to the same domain
of cellular CD4 that interacts with gp120 to yield effective therapeutics has been investigated
extensively [75, 142–145]. Our study, in addition to describing the phenotype resulting from
CD4low adaptation, highlights potential routes of escape from CD4 blocking. The envelope
adapted to CD4-blocking gains a wider cellular tropism by an increased ability to bind to CD4,
raising the possibility that blocking access to CD4 therapeutically could potentially accelerate
the generation of envelope variants found normally in late disease stages with increased CD4
binding affinity. The CD4low adapted envelopes generated in our in vitro system, as well as one
brain-derived envelope (B33) developed high neutralization sensitivity in parallel with CD4
affinity, which suggests for B33 that it may also have developed in the absence of nAb pressure.
Intriguingly, a macrophage-tropic isolate derived from plasma (C98-15), which evidently must
have been exposed to neutralizing antibodies, retained neutralization resistance despite devel-
oping the other features required for macrophage tropism. The same was true for the CNS
derived virus B59 opening the possibility that this strain encountered neutralization pressure
as well. Both C98-15 and B59 showed a less extreme phenotype in the entry kinetics compared
to the CD4low viruses and B33. However, in both cases the same trend in kinetics shift was evi-
dent in comparison to non-macrophage-tropic Envs from the same patients (Fig 7). Consider-
ing the potential danger of widening the host cell repertoire, administering CD4 derivatives
rather than targeting CD4 and the CD4bs directly may be more advisable. That this leads to
potent suppression has been shown in the past for CD4-IgG2 (aka Pro542; [146, 147]), and
small-molecule CD4 mimetics [148–151] and with currently unexcelled potency for eCD4-Ig
[152]. However, escape pathways for these compounds also need to be meticulously explored
to exclude changes in the host cell repertoire and unfavorable alterations in viral fitness. Thus
far only few studies have been dedicated to study escape from CD4 mimicking and soluble
compounds [153, 154], with more effort defining escape from CD4bs specific Abs elucidating
fitness costs associated with escape [155].
In sum our analysis describes a set of phenotypic features directly associated with CD4low
adaptation of one subtype B envelope in the absence of nAb pressure that is consistent with
phenotypic changes found in two CNS-derived Envs. We have also connected some of these
phenotypes to envelopes of primary patient isolates suggesting that the environment where
they evolved in vivo potentially shares features with the microenvironment we generated in
vitro. The phenotypic changes that came alongside the adaptation to use low levels of CD4, in
particular the alterations in entry kinetics and stoichiometry, trimer content and infectivity
may open means to better understand the limitations that evolution of CNS macrophage tro-
pism faces. Mechanistic studies on larger sets of CNS and peripheral macrophages may thus
aid to inform vaccine design towards limiting macrophage tropism, ideally preventing the
spread of infection into the CNS.
Materials and methods
Ethics statement
Peripheral blood mononuclear cells (PBMC) were purified from buffy coats from anonymous
blood donations from healthy individuals obtained by the Zurich Blood Transfusion Service
(http://www.zhbsd.ch/) under a protocol approved by the local ethics committee.
Patient plasma from twenty-four individuals with chronic HIV-1 subtype A (N = 4), B
(N = 11), C (N = 3), CRF_01_AE (N = 3), or CRF_02_AG (N = 3) infections were obtained
from biobank samples previously collected during three approved clinical trials the Swiss
Spanish treatment interruption trial (SSITT), the Swiss HIV Cohort study (http://www.shcs.
ch) and the Zurich Primary HIV-infection (ZPHI) study (ClinicalTrials.gov identifier
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NCT00537966) [156–160]. Written informed consent was obtained from all individuals
according to the respective studies as stated in the quoted publication according to the guide-
lines of Canton Zurich and the local ethics committee of all participating clinics.
Reagents
We thank the following individuals for providing inhibitors, antibodies and antibody expres-
sion vectors either directly, or via the NIH AIDS Research and Reference Reagent Program
(NIH ARP): W. Olsen (Progenics, Tarrytown, New York, USA) for CD4-IgG2 and PRO140;
D. Burton (The Scripps Research Institute, La Jolla, California, USA) for b6, b12, PGT121,
PGT128, PGT145, Z13eI; J. Mascola (VRC, Bethesda, Maryland, USA) for VRC01; M. Nus-
senzweig (The Rockefeller University, New York, USA) for 1–79; J. Robinson (Tulane Univer-
sity, New Orleans, USA) for 17b; D. Katinger (Polymun Scientific, Vienna, Austria) for 2G12,
4E10, and 2F5; and Marc Connors (NIC, Bethesda, Maryland, USA) for 10E8. 447-52d was
purchased from Polymun Scientific, Vienna, Austria; T-20 from Roche Pharmaceuticals,
Basel, Switzerland; and Maraviroc from Pfizer, UK. Human CD4 specific DARPins 55.2 and
57.2 were expressed as described (Schweizer, Rusert et al. 2008 [75]). A detailed list of all inhib-
itors and antibodies with their specifications can be found in S1 Table.
Cell lines
293-T cells (American Type Culture Collection (ATCC)) and TZM-bl cells ([161], obtained
from the NIH ARP) were cultivated in DMEM with 10% heat inactivated FCS and 1% Penicil-
lin/ Streptomycin. Rhesus Monkey Trim5α expressing TZM-bl cells (TZM-blrhTRIM5α) were
generated as described [131]. A3.01-CCR5 cells [131] were maintained in RPMI with 10% heat
inactivated FCS and 1% Penicillin/Streptomycin. Affinofile cells [90, 91] were thawed every
two months and maintained in DMEM media supplemented with 10% dialyzed fetal bovine
serum and 50μg/ml Blasticidin (Invitrogen, Massachusetts, USA).
Peripheral Blood Mononuclear Cells (PBMC)
Healthy donor PBMC were isolated from buffy coats and stimulated as described [162] and
cultivated in RPMI with 10% heat inactivated FCS, 1% Penicillin/Streptomycin and 100 units/
ml (U) human recombinant IL-2 (Hoffmann-La Roche, Basel, Switzerland).
NAB01 and NAB01-PA envelopes and generation of Env-chimeric,
replication competent TN6 viruses
The cloning of the CCR5-tropic subtype B envelope NAB-01 (previously described as
NAB1pre-cl_39x (GenBank database entry EU023918; (http://www.ncbi.nlm.nih.gov/
GenBank/index.html; [84]), which was derived from the virus isolate of a chronic infected
individual, patient NAB01 [82], has been previously described [84, 162]. After 39 weeks of
adaptation of the NAB01 isolate to PBMC culture, envelope genes of the adapted virus were
cloned from culture supernatant. One clone, termed NAB01 PBMC-adapted (PA), was
selected for follow up as representative culture adapted clone as it harbored mutations in V84I
and S190R, that were previously observed in PBMC adaptation of NAB01 clones ([84] and
EF643665, EF643666, EF643668-EF643670, EF643673-EF643675). The Env NAB01-PA was
then cloned into the replication competent TN6 HIV vector backbone [85] to produce the
Env-chimeric virus NAB01-PA-TN6 [84] which was used as starting point for the CD4low
adaptation. Of note, chimeric envelopes inserted into the TN6 backbone receive the signal
peptide and first three amino acids of Env from the original TN6 NL4-3 Env.
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Adaptation of NAB01-PA to CD4low expressing target cells
To follow the evolution of NAB01-PA in a low CD4 environment, NAB01-PA-TN6 was pas-
saged on PBMC in the presence of increasing concentrations of a CD4 inhibitor, the high-
affinity CD4-binding DARPin 57.2 that efficiently blocks HIV-1 gp120 binding to CD4 [75].
In a parallel control culture, NAB01-PA-TN6 was propagated on the same batches of PBMCs
in the absence of the CD4 blocking agent. After 18 weeks of culture and a final maximal con-
centration of 1.5 μM DARPin 57.2 (Fig 1B), several functional envelope clones capable of free-
virus TZM-bl infection were isolated from both the CD4-DARPin treated and control culture
supernatants by RT-PCR (S2 Table). Two unique envelopes, CD4low.c21 and CD4low.c24, rep-
resenting the main mutation patterns observed, were selected for further follow up (S2 Table).
To study whether the phenotype of the derived CD4low.c21 and CD4low.c24 clones is stable or
reverts to wild type once back in a CD4 high environment, CD4low.c21, CD4low.c24 and
PBMCcon.c14 TN6 chimeras were further cultured for eight weeks on untreated PBMCs in the
absence of CD4-binding DARPin. After eight weeks, functional envelope genes were isolated
from each of the reversion cultures, and representative clones referred to as CD4low.c21-rev,
CD4low.c24-rev and PBMCcon.c14-rev (rev = reversion culture) chosen for follow up. All enve-
lopes selected for follow up were cloned into pcDNA3.1 expression vector (Invitrogen, Carls-
bad, California, USA) as described [84] to allow phenotypic characterization of cell expressed
envelopes and Env-pseudoviruses (see below) and further cloned into the TN6 vector to create
replication competent chimera.
Patient derived paired macrophage and non-macrophage-tropic
envelopes
The previously described patient-derived paired macrophage and non-macrophage-tropic
envelopes (B33, LN40/B33, B59, LN8, C98-15, and C98-27 [64, 76–79]) were re-cloned from
pSVIII plasmids into pcDNA3.1 expressions plasmids by AT-overhang ligation to allow direct
comparison with the CD4low virus panel.
Envelope pseudotyped HIV-1 luciferase reporter virus
Envelope pseudotyped HIV-1 were produced as described [162]. Briefly, 293T cells were trans-
fected with pcDNA3.1 plasmids encoding the respective envelope genes and the Luciferase
expressing HIV-1 backbone pNLluc-AM (gift from A.J. Marozsan and J.P. Moore) at a ratio of
1:3 using polyethylenimine (PEI, linear 25 kDa, Polysciences, Eppelheim, Germany). After 8-
16h of transfection, medium was replaced with fresh culture medium. Pseudovirus superna-
tant was collected 48h post transfection and filtered through 20 μm pore micro filters. Filtrates
were then either stored at -80˚C or ultra-centrifuged at 49’000g and 4˚C for 90 minutes and
suspended in PBS before being stored at -80C. Envelope-pseudotyped virus expressing mouse
CD4 was produced as previously described [96].
Pseudovirus inhibition assays
Pseudovirus inhibition assays were performed using TZM-bl cells and PBMC as previously
described [162, 163]. Briefly, serial dilutions of inhibitors were pre-incubated with target cells
or viruses depending on target epitope, for 1hr at 37˚C, then virus, cells, and inhibitor were
added together and incubated for 48–72 hours. Infection supernatants were then aspirated,
cells lysed, luciferase substrate (Promega, Madison Wisconsin, USA) added and the presence
of luciferase quantified by measuring relative light units (RLU) using a Dynex MLX 96-well
plate reader.
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CD4 binding activity of Env variants
To estimate CD4 binding activity of Env variants, we performed a cell-based envelope binding
assay. 293-T cells were transfected with pCMV-rev and envelope encoding pcDNA3.1 plas-
mids in a 1:4 ratio with polyethyleneimine (PEI, linear 25 kDa, Polysciences, Eppelheim, Ger-
many) and incubated for 36 hours to induce membrane expression of the envelope. CD4
binding activity of cell surface expressed Env was analyzed by flow cytometry using biotin
labelled CD4- IgG2 and detection with streptavidin-PE (BD, New Jersey, USA).
Monitoring dependence on receptor levels by infection of Affinofile cells
CD4 and CCR5 dual-expressing 293-T Affinofile cells were induced and infected in a matrix
layout as previously described [90, 91]. Briefly, 1.2x105 or 1x104 cells were seeded per well of a
24-well culture plate for quantitative flow cytometry of CD4 and CCR5 expression levels, or
96-well clear-bottom culture plate for infections, respectively, and allowed to adhere overnight
before being treated with perpendicular serial dilutions of Doxycycline (Sigma Aldrich, Mis-
souri, USA) and Ponasterone A (Invitrogen, Massachusetts, USA) to induce CD4 and CCR5
expression, respectively. Surface expression levels of CD4 and CCR5 were quantified between
18-24h post induction by quantitative flow cytometry using QuantiBRITE beads and PE-
labelled antibodies specific for CD4 (clone Q4120; Sigma Aldrich, Missouri, USA) and CCR5
(clone 2D7; BD Biosciences, New Jersey, USA). Affinofile cells were infected 18-24hrs post-
induction using 105 RLU of virus per well (calculated by titration on TZM-bl cells) in the pres-
ence of 10 μg/ml Diethylaminoethyl (DEAE; Ammersham plc, UK) and luciferase readout was
performed after 48hrs of infection.
Cell-cell transmission
To specifically measure viral infectivity in cell-cell transmission, we employed a recently
described A3.01-CCR5 cell based assay [95]. Briefly, this assay utilizes an NL4-3 derived pseu-
dotyped HIV-1 backbone with an intron-regulated Gaussia luciferase LTR-reporter construct
called inGluc which is co-transfected with an Env expression plasmid into 293-T donor cells
[13, 16, 164], a kind gift from Dr. M Johnson. The reverse orientation of the reporter and the
intron allow luciferase expression only after correct splicing, packaging into viral particles and
infection of and expression in the A3.01-CCR5 target cells. Free virus infection was restricted
by the omission of DEAE in the infection medium as described previously [131].
To measure infectivity in free virus and cell-cell transmission, 2.5x105 293-T cells per 6-well
were transfected with Env expression plasmid and NLinGluc backbone for cell-cell in a 1:3
ratio, using polyethylenimine (PEI) as transfection reagent. To test cell-cell infectivity, the cells
were detached after six hours of incubation and 5x103 cells were seeded in 100 μl per 96 well.
1.5x104 A3.01-CCR5 target cells in 100 μl RPMI medium were added to the 293-T cells per 96
well. After 60 h of incubation at 37˚C, Gaussia luciferase activity in the supernatant was quan-
tified using the Renilla Luciferase Assay System (Promega, Madison Wisconsin, USA) accord-
ing to the manufacturer’s instructions.
Cell fusion assay
We employed a co-culture of HIV-1 pseudovirus transfected 293-T cells and the LTR-firefly
luciferase reporter expressing TZM-bl cells to obtain information on the fusion potential of
the probed envelope clones. To limit influence of free virus in the readout, we used TZM-bl
cells that express rhesus macaque Trim5α, as expression of rhTrim5α in target cells restricts
free virus infection [95, 131]. 293-T cells were PEI transfected for six hours with env-
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pcDNA3.1 and pNL AM GFP backbone. Transfected cells were then detached, washed once at
300g for 3min, suspended in 1200μl culture medium and 100μl were added to 10 replicate
wells of a clear-bottom 96 well plate containing 1.5x104 TZM-blrhTrim5α in the presence or
absence of inhibitors. After 24 hours, luciferase activity was recorded.
Detection of gp120 shedding
Gp120 shedding following treatment with 2F5 was measured as previously described [96].
Envelope-pseudotyped virus carrying mouse CD4 (mCD4) were ultracentrifuged at 49’000g
for 90 minutes at 4˚C. The virus pellet was resuspended in TBS +2% BSA for 120–200 minutes
at room temperature and treated with 100 μg/ml of mAb 2F5 for 18–20 hours at 37˚C. Virions
were immobilized with magnetic Dynabeads coated with rat mAb L3T4 specific for mCD4
(Thermo Fisher, Massachusetts, USA) using a magnetic tube rack (DynaMag-2, Thermo
Fisher, Massachusetts, USA) and washed twice to remove shed gp120 and non-bound virions.
Captured viral particles were lysed with TBS +1% Empigen and gp120 and p24 content mea-
sured by ELISA. The gp120 content was normalized to p24 content of each sample and shed-
ding was expressed as a percentage of the mock-treated controls.
HIV-1 infection of primary monocyte-derived-macrophage cultures
Monocytes were purified from freshly isolated healthy donor PBMC using MACS anti-
CD14-coated magnetic beads and MACS separation columns (Miltenyi Biotec, Germany).
Purity of viable cells ranged between 96–98% as assessed by CD14+ staining in flow cytometry
(CD14-PE from Life-Technologies; IgG2a-PE Isotype from BD Pharmingen; Live-Dead near
infra-red viability stain from Life Technologies; pooled mouse serum used to block fc receptors
at 20% (gift of L. Hangartner). 5x104 monocytes per well were seeded into 96-well culture
plates (Greiner Bio-One GmbH, Germany) for infection experiments, or 2x106 cells per well
seeded ultra-low attachment surface 6-well plates (Sigma Aldrich, Missouri, USA) for flow
cytometry analysis. Monocytes were differentiated for six days in differentiation medium
(RPMI1640 supplemented with 1% Pen/strep, 10% fetal-calf serum, 5% pooled human AB
serum (Sigma Aldrich, Missouri, USA), 4mM Glutamax (Thermo Fisher, Massachusetts,
USA)) and either 100ng/ml M-CSF or 100ng/ml GM-CSF (Immunotools GmbH, Friesoythe,
Germany) to produce two different phenotypes of monocyte-derived-macrophages [165–167],
known to express differential levels of CD4 and CCR5 [29]. After six days of differentiation @
37˚C in 80% humidity and 5% CO2, differentiation medium was replaced with culture
medium (RPMI 1640, 10% FCS, 1% penicillin and streptomycin) and incubated at 37˚C over-
night. Pseudovirus infections and flow cytometry of surface receptors were performed on day
seven post-isolation. Before infecting MDMs, one well of each MDM type was imaged with an
Incucyte ZOOM system using a 10x objective lens and ‘scan-on-demand’ with the phase con-
trast channel. Cell morphology was compared to [166] to confirm cultures were independently
differentiated as one phenotype or the other by the presence of ‘fried egg’ morphology for
G-MDM, and ‘spindle-cells’ for M-MDM (S4A Fig). Envelope pseudotyped virus supernatants
were titrated onto MDMs and allowed to incubate at 37˚C in 80% humidity and 5% CO2 for
seven days. Firefly luciferase production was measured using a Dynex MLX plate reader (high
gain setting) and Bright-Glo Luciferase Assay System (Promega, Madison Wisconsin, USA)
on day 14 post-isolation (day seven post infection). To analyze surface marker expression,
MDM were detached with cell dissociation solution (Sigma Aldrich, Missouri, USA) and
stained with CD4-PE (BD, New Jersey, USA), CD195-PE (Biolegend, California, USA, Califor-
nia, USA), CD64-FITC (Biolegend, California, USA), or CD163-BV421 (Biolegend, California,
USA) mAbs, or matched isotype controls, to measure expression of HIV receptors CD4 and
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CCR5(CD195) and macrophage differential phenotypic markers CD64 and CD163 [168](S4A
Fig). Pooled mouse serum (gift of L. Hangartner) was added at 20% to all staining solutions to
block unspecific binding of mouse mAbs to MDM Fc receptors.
Envelope sequencing and analysis
Cloned envelope genes were sequenced on an ABI 3130xl genetic analyzer (Applied Biosys-
tems, Rotkreuz, Switzerland) as described [84]. Gp160 protein characteristics were calculated
using ProtCalc for charge (http://protcalc.sourceforge.net/) and the NIH N-GlycoSite tool
(http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html) to count potential
glycosylation sites. Mutation prevalence in the Los Alamos National Laboratory HIV sequence
database was performed using QuickAlign (https://www.hiv.lanl.gov/content/sequence/
QUICK_ALIGNv2/QuickAlign.html) web alignment with all 4907 complete sequences avail-
able at the time of query. Subtype and Tissue ontogeny- filtered sequences were downloaded
from the HIVbrainseqDB [102] and the prevalence of specific mutations queried using a cus-
tom algorithm, available on request. Envelope gene sequences of all clones were deposited in
the GenBank database entries KX673206-KX673212.
Entry kinetics
Time of inhibitor addition experiments were performed to define entry kinetics with small
modifications to previously described protocols [112, 169]. Briefly, 6x103 TZM-bl cells in
DMEM supplemented with 10 μg/ml DEAE-Dextran were plated in 384 well clear-bottom
plates (Greiner Bio-One GmbH, Germany). Luciferase reporter pseudovirus was spinoculated
onto cells for 30min at 2095g and 4˚C to settle virus onto cells but prevent receptor engage-
ment. Following spinoculation the supernatant with un-adsorbed virus was removed and 70 μl
of 37˚C pre-warmed DMEM were added per well to initiate infection (time point zero) and
plates were incubated at 37˚C. At defined time points post-infection, 10 μl of the respective
inhibitor were added to specific wells to stop the viral entry process. Inhibitors (T-20, Mara-
viroc, and DARPin 55.2) were added at saturating concentrations (final concentrations of
50 μg/ml, 5 μM and 1 μM, respectively) to ensure inhibition of entry. To obtain a measure for
infectivity across different experiments, the wells with the last inhibitor addition at 120 min-
utes after infection start were used as 100% reference infectivity value and the infectivity of all
other inhibitor treated wells were set in relation to it. In addition, a mock-treated well (addi-
tion of 10 μl DMEM at time point zero) was evaluated to assess absolute infectivity in absence
of inhibitors. Luciferase reporter readout was performed after 48hr incubation at 37˚C.
The time to reach 50% of the 120min infection (T½) was used as a surrogate for timing of
receptor (CD4 or CCR5) binding or fusion. For each envelope, each inhibitor and each repli-
cate, a general kinetic equation (A-D)/(1+/(x/C)^B) + D was fitted to each replicate time series
of data points and a T½ value was estimated from the fitted equation. If the least-squares
approximation used to fit the kinetic equation did not converge, a straight line was instead
used to estimate T½. To deal with irregularities of the data, this line connects the data point
left of the first point with>50% relative infectivity and the point right of the last point with
<50% relative infectivity. The reported T½ value for each envelope and each inhibitor is the
mean T½ value across all replicates (see Figs 6 and 7). Mann-Whitney tests were performed to
compare the time intervals between the four stages of the entry process (synchronized start,
CD4 binding, CCR5 attachment, fusion) among different envelopes. Only envelopes derived
from the same patient were compared (see Fig 7 and S6 Fig).
To assess the sensitivity of the method used, we estimated T½ values in two different ways
in addition to the method described above (see S7 Table). First, we took the mean or median
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of the data points from all replicate experiments prior to fitting only one curve and estimating
T½. Since each experiment always consisted of two replicates, the second method took the
mean or median of these two data points, fitted curves to these data, estimated T½ values for
each pair and averaged them across experiments (see S7 Table). Whenever taking an average,
we also considered using the median instead of the mean (see S7 Table).
Estimating the stoichiometry of entry
The number of envelope glycoproteins required for target cell entry of the studied envelope
variants was calculated as previously described [112–114]. In short, we generated dominant
negative envelope genes in the pcDNA3.1 vector by knocking out the furin cleavage site
(R508S/R511S). Ratios of the dominant negative mutant and wild-type envelopes were trans-
fected into 293-T cells along with the NL-Luc-AM HIV-1 backbone to generate pseudotyped
viral particles carrying varying ratios of functional and non-functional envelopes. Pseudovirus
was then titrated on TZMbl target cells and read out after 48hrs using a Dynex MLX plate
reader and Bright-Glo Luciferase Assay System (Promega, Madison Wisconsin, USA).
The number of envelope proteins per viral particle was estimated by quantitative ELISA of
gp120 and p24, as previously described [112], and the mean trimer number of each virus vari-
ant determined. These data were then used to determine the number of trimers required for
entry using the mathematical framework described in [112–114].
Supporting information
S1 Table. Inhibitors and antibodies.
(TIF)
S2 Table. Overview Env mutation in clones isolated from CD4low and reversion culturing.
(TIF)
S3 Table. Multi-clade virus panel probed for CD4-DARPin 55.2 sensitivity.
(TIF)
S4 Table. CD4low adaptation panel sequence characteristics.
(TIF)
S5 Table. Patient isolate pairs of macrophage- and non-macrophage-tropic envelopes.
(TIF)
S6 Table. Inhibitory activity of CD4 and CCR5 inhibitors against CD4low adapted viruses
during free-virus infection and fusion.
(TIF)
S7 Table. Entry kinetics curve fitting sensitivity analysis.
(TIF)
S8 Table. Estimations of trimer number per virion by quantitative gp120 and p24 ELISA
ratios.
(TIF)
S1 Fig. Differential infection of Affinofile cells with varying CD4 and CCR5 levels by
CD4low adapted viruses. 293-T Affinofiles were induced to express forty-two unique combina-
tions of (A) CD4 and (B) CCR5 levels. Receptor levels were assessed by quantitative flow cytom-
etry. Data are from one of two independent experiments. (C) and (D) Infection of Affinofile
matrices. Following receptor induction Affinofiles were infected with the indicated envelope
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pseudotyped viruses. For each pseudovirus, infection across the Affinofile matrix was normal-
ized to the maximum infection this virus reached on Affinofiles in an individual experiment.
Data from two independent experiments are shown, error bars = SD. (C) Mean percent maxi-
mum infections were plotted by CD4 level. Each panel indicates one level of CD4 induction
with CCR5 levels increasing from left to right within each cluster of colored bars. (D) Mean per-
cent maximum infections were plotted by CCR5 level. Each panel indicates one level of CCR5
induction with CD4 levels increasing from left to right within each cluster of colored bars.
(TIF)
S2 Fig. Three dimensional Affinofile infection profiles. Affinofiles were induced to express
forty-two unique combinations of CD4 and CCR5 and infected with the indicated Env-pseu-
doviruses. Data of the CD4low envelope panel shown in S1 Fig and primary virus JR-FL for
comparison are depicted. Two independent assays are shown. Axes legends are indicated at
top right, dotted line projects into the page.
(TIF)
S3 Fig. Comparison of free virus, cell-cell transmission and fusion capacity of CD4low
adapted viruses. Data correspond to Fig 3 and depict raw RLU values obtained for the
depicted experiments (A) Titration of Env pseudoviruses on TZM-bl and PBMC. Infectivity of
CD4low adapted viruses in (B) cell-cell transmission and (C) fusion.
(TIF)
S4 Fig. Infectivity of CD4low adapted viruses on macrophages. Differentially conditioned
monocyte derived macrophage phenotypes and infection. (A) Phenotypic verification of
M-MDM and G-MDM preparation by phase contrast morphology and flow cytometry analy-
sis of CD4, CD64 and CD163. Histograms depict one of 2 independent experiments for
CD163 and CD64 staining, and one of 4 independent experiments for CD4 staining, dot-plot
shows trends of CD4 and CCR5 staining levels for four independently isolated and treated
batches of MDM. (B) Envelope pseudotyped virus stocks were freshly produced by transfecting
293-T cells with pcDNA3.1 envelope expression plasmid together with pNLluc-AM backbone
and viral stocks titrated on M-MDM and G-MDM of eight different donors. Data show sum-
mary of experiments that were normalized either by input volume, RLU value determined by
TZM-bl infectivity (RLU/μl), or p24 as determined by ELISA of viral stocks. Infection readout
was normalized to NAB01. (C) Absolute infectivity of ultracentrifugation purified Env-pseu-
dovirus stocks on differentially M-MDM and G-MDM with virus input normalized by p24
content. Mean, error bars = SD.
(TIF)
S5 Fig. Prevalence of key mutations observed upon adaptation to CD4low targets amongst
primary viruses recorded in the Los Alamos sequence database. 4907 available Env
sequences were analyzed.
(TIF)
S6 Fig. Statistical analysis of entry kinetics following paired curve fitting. Alternative analy-
sis of transition time between steps of the entry process of the data depicted in Fig 7. Data
points from the two replicates from the same experiment were combined (i.e. paired) before
fitting the curves and averaging individual T½ values. Estimated time intervals between the
four stages of the entry process (synchronized start, CD4 binding, CCR5 attachment, fusion)
were compared by Mann-Whitney tests. Only envelopes from the same patient (same principal
color) were compared.
(TIF)
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S7 Fig. Comparison of free virus, cell-cell transmission and fusion capacity of patient-
matched macrophage tropic and non-macrophage-tropic viruses. Data correspond to Fig 8
and depicts raw RLU values obtained for the (A) titration of Env pseudoviruses on TZM-bl
and infectivity of CD4low adapted viruses in (B) cell-cell transmission and (C) fusion.
(TIF)
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